Mankind Pharma has announced the acquisition of the Rivotril brand from Roche for the Indian market, marking a significant strategic move to strengthen its central nervous system (CNS) treatment portfolio. The pharmaceutical company has secured comprehensive exclusive rights for manufacturing, marketing, and distribution of this neurological medication within India.

Strategic Brand Acquisition from Roche

The acquisition of Rivotril represents a focused expansion into the CNS therapeutic segment for the pharmaceutical company. Rivotril is the innovator/reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. Often regarded as a textbook brand in its category with strong clinical legacy, this acquisition further strengthens Mankind Pharma's presence in the CNS therapy segment.

Strategic Focus on Chronic Therapies

The acquisition builds on Mankind Pharma's growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company's overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders.

Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, stated: "This acquisition is aligned with our strategic focus on strengthening our presence in chronic therapies and specialty therapies. Going forward, we see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS therapy area."

Market Positioning and Distribution Network

Mankind Pharma will leverage its nationwide distribution network and large field force to support wider access to Rivotril across healthcare institutions and prescribers in India. The company currently engages with over 5 lakh doctors and has built a strong prescription share in the Indian pharmaceutical market, enabling deep penetration across urban and semi-urban markets.

The addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen the company's CNS portfolio and expand treatment options for patients managing neurological conditions. This strategic move creates a platform for future expansion through potential line extensions in the CNS therapy area.

Source: None/Company/INE634S01028/83caccd9-2c57-4a19-b8f5-a493d18f3e84.pdf

Mankind Pharma Limited has completed the allotment of 23,256 equity shares under its Employee Stock Option Plan 2022, as approved by the Nomination and Remuneration Committee through a circular resolution passed on March 16, 2026. The shares were allotted to eligible employees who exercised their stock options under the company's ESOP scheme.

Share Allotment Details

The allotment represents a strategic move to reward employee participation in the company's growth through equity ownership. The key parameters of this ESOP allotment are structured as follows:

Impact on Share Capital

The allotment has resulted in an expansion of the company's equity base, reflecting the successful implementation of its employee incentive program. The capital structure changes are detailed below:

Regulatory Compliance and Share Characteristics

The allotment has been executed in compliance with Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly issued shares carry the same rights and privileges as existing equity shares, with no lock-in restrictions applicable.

Key regulatory aspects include:

• SEBI Filing Reference: Originally filed on September 27, 2023
• Stock Exchange Listing: NSE and BSE
• ISIN Number: INE634S01028
• Share Ranking: Pari-passu with existing equity shares

Corporate Governance Framework

The ESOP allotment demonstrates Mankind Pharma's commitment to aligning employee interests with shareholder value creation. The Employee Stock Option Plan 2022 serves as a retention and motivation tool for eligible employees, allowing them to participate in the company's long-term growth trajectory.

The company has fulfilled all disclosure requirements by informing both NSE and BSE about the allotment and updating the information on its official website at www.mankindpharma.com . This transparent approach ensures all stakeholders remain informed about changes in the company's capital structure.